CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Gyre Therapeutics Inc - GYRE CFD

11.1066
0.54%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.1968
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024346 %
Charges from full value of position ($-4.63)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024346%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002124 %
Charges from full value of position ($0.40)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.002124%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 11.0366
Open 12.0866
1-Year Change -50.46%
Day's Range 11.0966 - 12.3566
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 17, 2024 11.0366 1.0200 10.18% 10.0166 11.3566 9.9666
Dec 16, 2024 9.9066 0.0300 0.30% 9.8766 10.2666 9.6366
Dec 13, 2024 9.6066 -0.2600 -2.64% 9.8666 10.0666 9.5766
Dec 12, 2024 9.7566 -0.3100 -3.08% 10.0666 10.4666 9.7166
Dec 11, 2024 9.9866 -0.9700 -8.85% 10.9566 10.9766 9.9866
Dec 10, 2024 10.9166 0.2000 1.87% 10.7166 11.2866 10.7166
Dec 9, 2024 10.6566 -0.9300 -8.03% 11.5866 12.4166 10.3166
Dec 6, 2024 11.4666 0.7300 6.80% 10.7366 11.5466 10.6666
Dec 5, 2024 10.4066 0.4300 4.31% 9.9766 10.8166 9.9766
Dec 4, 2024 9.8766 -1.2400 -11.15% 11.1166 11.2866 9.4966
Dec 3, 2024 10.9766 -0.8900 -7.50% 11.8666 12.0766 10.9666
Dec 2, 2024 11.7866 -0.9800 -7.68% 12.7666 12.7666 11.7366
Nov 29, 2024 12.4666 0.4300 3.57% 12.0366 13.0666 12.0366
Nov 27, 2024 11.6266 -0.7300 -5.91% 12.3566 12.3566 11.4666
Nov 26, 2024 11.9766 0.3600 3.10% 11.6166 12.3666 11.6166
Nov 25, 2024 11.6066 0.1300 1.13% 11.4766 12.1666 11.4766
Nov 22, 2024 11.2566 -0.7100 -5.93% 11.9666 12.0766 11.0066
Nov 21, 2024 11.6866 -1.0800 -8.46% 12.7666 12.8266 11.6766
Nov 20, 2024 12.8866 -0.0200 -0.15% 12.9066 13.1166 12.7466
Nov 19, 2024 12.8866 0.3000 2.38% 12.5866 13.0666 12.3366

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Catalyst Biosciences, Inc. Company profile

About Catalyst Biosciences Inc

Catalyst Biosciences, Inc., formerly Targacept, Inc. is a research and clinical development biopharmaceutical company. The Company is focused on medical needs in disorders of the complement and coagulation systems. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously (SQ) administered engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders in patients with Hemophilia A or B with inhibitors. Its clinical trial of MarzAA in Factor VII Deficiency, Glanzmann Thrombasthenia, and Hemophilia A with inhibitor patients on prophylaxis Hemlibra for treatment of episodic bleeding (MAA-202). The Company pipeline also includes dalcinonacog alfa (DalcA), a subcutaneously (SQ) Factor IX (FIX) to prevent bleeding episodes for Hemophilia B patients. Its discovery stage Factor IX gene therapy construct, CB 2679d-GT for Hemophilia B.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Catalyst Biosciences Inc revenues decreased 74% to $4.9M. Net loss increased 81% to $67.6M. Revenues reflect License decrease from $15.1M to $0K. Higher net loss reflects Research and development increase of 3% to $38.3M (expense), General and administrative - Balancing v increase of 9% to $11.3M (expense), Miscellaneous income (expense) decrease of 99% to $8K (income).

Equity composition

Common Stock $.001 Par, 04/11, 100M auth., 29,021,460 issd., Insiders control approx. 0.08%. IPO: 4/06 5,000,000 shs. @ $9per share by Deutsche Bank Securities. 8/15, 1-for-7 reverse stock split.

Industry: Biotechnology & Medical Research (NEC)

12770 High Bluff Drive, Suite 150
SAN DIEGO
CALIFORNIA 92130
US

People also watch

Gold

2,617.00 Price
-0.770% 1D Chg, %
Long position overnight fee -0.0083%
Short position overnight fee 0.0001%
Overnight fee time 22:00 (UTC)
Spread 0.30

XRP/USD

2.47 Price
-4.530% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01232

BTC/USD

103,674.30 Price
-2.060% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

US100

21,804.20 Price
-0.330% 1D Chg, %
Long position overnight fee -0.0243%
Short position overnight fee 0.0021%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading